Next-Generation Sequencing (NGS) Archives

Takeda’s Exkivity Approved by U.S. FDA as First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

Adults, Approvals, Clinical Trials, EGFR exon 20 insertion mutations, FDA, Metastatic non-small cell lung cancer, Next-Generation Sequencing (NGS), Platinum-Based Chemotherapy, R&D, Takeda, Therapeutics

The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Exkivity (mobocertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics

Business, Collaborations, Companion Diagnostics, Deals, Next-Generation Sequencing (NGS), Precision Medicine

Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies.

Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device

Antibody Drug Conjugates (ADC), Business, Clinical Data, Clinical Trials, Companion Diagnostics, Diagnostic Tools, HER2 Mutations, Next-Generation Sequencing (NGS), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Partnerships, R&D

Thermo Fisher Scientific and Daiichi Sankyo have partnered to co-develop a companion diagnostic device for patients who have non-small cell lung cancer (NSCLC).